Phase 2 Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with mild cognitive impairment related to Alzheimer's disease, following recognised medical guidelines
- People whose thinking and memory are currently normal but who have at least one of the following risk factors for Alzheimer's disease: carrying a specific gene variant called APOE ε4; having concerns about their own memory with a low score on a standard memory questionnaire; or having a parent or sibling who has had dementia
- People who are at least 55 years old
- People with a body weight that falls within a moderate range — specifically, a body mass index (a measure of weight relative to height) between 17 and 30
- Women who have been through menopause
- People who do not smoke
- People who have someone in their life (such as a family member or close friend) who has regular contact with them for 10 or more hours per week and can report independently on how the person is functioning day to day
- People whose first language is English
- People who are in generally good health, with no conditions expected to interfere with the study
- People who are willing and able to take part for the full duration of the study
Who may not be able to join:
- People who are participating in another therapeutic clinical trial at any time during this study
- People whose heart electrical activity shows an abnormal reading on a specific measurement (called a corrected QT interval), above certain thresholds for men and women (confirm with trial site)
- People who have a significant neurological condition other than possible early Alzheimer's disease, such as Parkinson's disease, Huntington's disease, multiple sclerosis, brain tumour, a history of seizures, or lasting effects from a significant head injury, among others
- People who have had major depression or bipolar disorder within the past year
- People with a history of alcohol or drug dependence
- People with a significant ongoing illness or unstable health condition that could make it difficult to follow the study requirements
- People who have had general surgery within the last 3 months
- People whose vision or hearing difficulties are significant enough to interfere with completing cognitive tests accurately
- People who have been treated in the last six months with antidepressants, antipsychotics, sleeping medications, or steroid medications called glucocorticoids
- People who have been treated in the last six months with certain medications that interact with specific liver enzymes (called CYP2C9 or CYP2C19), most notably a blood-thinning medication called clopidogrel or medications for stomach acid called proton pump inhibitors (confirm with trial site)
- People currently using certain substances that interact with a liver enzyme called CYP3A, including grapefruit juice or the herbal supplement St. John's Wort
- Note: The trial's lead researcher may consider exceptions to some of these criteria on a case-by-case basis
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Cynthia A Munro, PhD, Johns Hopkins School of Medicine
Phone: 410-550-2036
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Memory as assessed by pattern separation task performance after 2 weeks of treatment with CORT108297; Memory as assessed by the Hopkins Verbal Learning Test-Revised Edition (HVLT-R) after 2 weeks of treatment with CORT108297; Executive functioning as assessed by the Trail Making Test (TMT), part B after 2 weeks of treatment with CORT108297; Executive functioning as assessed by the Digit Span Task (digit span backwards) after 2 weeks of treatment with CORT108297
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.